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Immunopathological study of a 330 kilodalton (KD) brush border (BB)
antigen. Role in Heymann's nephrltis (HN). P. Ronco, J.T., Neale, C.B.
Wilson, and P. Verroust. INSERM U64, Hopital Tenon, Paris, France,
and Scripps Clinic and Research Foundation, La Jolla, California,
USA. Since gp 330 was identified by Keijaschki and Farquhar, several
groups have implicated in HN antigens of different molecular weight
(150 to 600 kd). While analyzing with monoclonal antibodies (Mab)
antigens expressed by BB and glomerulus, we identified a 330 kd
protein localized in the coated pits of glomerular podocytes. We
demonstrate here that this antigen is involved in HN. (1) The antigen is
specifically bound by Ig eluted from glomeruli of rats with HN and by
antibodies to the nephritogenic fraction RTE&5 purified by Edgington,
Glassock, and Dixon in 1968. (2) Active immunization of Lewis rats
with the antigen purified by affinity chromatography using S4B coupled
Mab induces proteinuric membranous HN. (3) 5/6 Mab specific for the
330 kb antigen can induce passive HN. These results confirm the data
of Keijaschki and Farquhar and further indicate that the 330 kd antigen
was a component of the purified antigen used by Edgington et al in 1968.
In addition, they demonstrate that this antigen can by itself include
clinically and histologically active HN, whereas the corresponding Mab
can induce passive HN. These data confirm the role of in situ formation
of Ig deposits in membranous glomerulonephritis.
Immunohistochemical study of the CSb-9 complex of complement in
diseased human kidneys: Diversity in localization and potentIal role in
tissue damage. N. Hinglais, M.D. Kazatchkine, S. Bhakdi, Ch. Mandet,
J. Grossetete, and J. Bariely. The presence and localization of the
C5b-9 neoantigens of the terminal complement sequence of C3c and
C3d antigens and of Factor H antigens have been studied by im-
munofluorescence in 67 biopsy specimens from patients with a wide
range of renal diseases with and without renal immune deposits. Seven
biopsy specimens were also studied by electron microscopy using
immunoperoxidase techniques. Biopsy specimens were classified into
three groups based on the pattern of glomerular staining with anti-CSb-
9. In the first group, a sparse mesangial labelling was seen, similar to
that which had been observed in morphologically normal kidneys. In
the second group, abundant clusters of C5b-9 were seen in enlarged
mesangial areas. In group III, C5b-9 neoantigens were found in the
same location as immune deposits. Immunoelectron microscopy dem-
onstrated the presence of C5b-9 neoantigens on cell remnants embed-
ded in connective matrices in all the specimens, the constant presence
of C5b-9 neoantigens on old and large immune deposits, and the
occasional presence of C5b-9 on recent and small immune deposits. The
data indicated: (1) The presence of C5b-9 neoantigens even in large
amounts, is not necessarily associated with immune deposits; (2) some
immune deposits of small size do not activate the whole complement
sequence, (3) the occurrence of proteinuria, in such cases, is indepen-
dent of the presence or absence of C5b-9 on immune deposits (for
example, membranous nephropathy, stage I), (4) in situ activation of
the complement system may be documented in the absence of detect-
able C3 (C3c) antigen in glomeruli; and (5) morphological alterations of
cells in the vicinity of immune deposits bearing C5b-9 are sparse and not
constantly observed. Thus, the presence of C5b-9 neoantigens of the
terminal complement sequence in pathological renal tissue does not
have an univocal significance and requires appropriate controls in order
to assess the potential role of C5b-9 in tissue damage in various types of
immunologically mediated and non-immune human nephropathies.
Successful treatment with cyclosporin of corticoresistant idiopathic
nephrotic syndrome (minimal change lipoid nephrosls and focal segmental
hyalinosis). A. Meyrier, P. Simon, G. Perret, and M.-C. Condamin-
Meyrier. Hopital Avicenne, Bobigny, and Hôpital La Bauchee, Saint-
Brieuc, France. The nephrotic syndrome (NS) of lipoid nephrosis (with
minimal or no glomerular lesions, MCLN and of focal segmental
hyalinosis (FSH) can be initially or secondarily resistant to corticoster-
oids and immunosuppressive agents. In such a case, the evolution of
relentless NS is a hazardous and debilitating condition, which may
eventually lead to end-stage renal failure. A functional disequilibrium
between T and B lymphocytes and the role of a lymphokine that
modifies glomerular permselectivity to proteins seem to play a patho-
genetic role in these two conditions. In this respect, we reasoned that
the mode of action of cyclosporin (CyA) could be compatible with a
favorable effect on the NS. We therefore undertook treatment with CyA
in four adults with corticoresistant NS. Renal function was normal or
slightly subnormal in all. There were two women, 25 and 59 years of
age, with MCLN and two men, 20 and 56 years of age, with FSH. The
patients with MCLN had initially been corticosensitive, then
corticodependent, and eventually corticoresistant. One case had re-
ceived immunosuppressive treatment. The two individuals with FHS
had been treated with corticosteroids, immunosuppressors, and, in one
case, plasmapheresis, before they became resistant to any form of
treatment. Mter a 28-day wash-out, ending in an 18-day placebo period,
CyA was given for 3 months, at an initial dosage of 5 mg/kg/24 hr, which
was subsequently adapted to keep whole blood levels in the range of 150
to 400 ng per liter. In one case of MCLN and in the two cases of FSH,
partial remission was achieved (that is, NS subsided but low-grade
proteinuria persisted), and, in one case of MCLN, complete remission
was observed. The therapeutic effect of CyA was apparent between
days 21 and 28. Renal and hepatic tolerance were good. In two of four
cases, serum creatinine even decreased, probably due to amelioration
of functional renal failure. This preliminary study shows that CyA is
capable of inducing remarkable improvement in NS in which a thera-
peutic dead end has been reached. Several issues remain that concern:
(1) the duration of the remission so obtained; (2) the advisable strategy
in case of recurrence; and (3) the long term tolerance of CyA in such
indications. Nonetheless, these observations show that CyA may
represent a major advance in the management of NS resisting any other
form of treatment. CyA could also be an immunologic tool of great
interest in better understanding the nosology and the physiopathology
of idiopathic NS.
Hemoglobinuria in bare-handed drummers. A. Baumelou, E. Miailhe,
B. Cohn, and G. Berniot. Nephrology Department, Piiié Hospital,
Paris, France. The emission of dark urine, provoked by bare-handed
drum beating, has been reported in only three case reports in the
literature to our knowledge. This study stems from a case we observed.
This work presents the results of history taking of 78 drummers and
various functional studies completed on 11 of them. The frequency of
this symptom was 61% in the population of drummers studied. It
occurred primarily in male black professional drummers playing
djembes or congas. The intensity and the length of drumming sessions
are greater in this group. The finding of the sickle cell trait might
constitute a factor for red blood cell (RBC) fragility in the black
patients. Non-visible pigmenturia after performance is very frequent.
Twenty-five post concert tests were performed on seven subjects using
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Nephur-test urine dipsticks. We observed 17 positive reactions of the
homogeneous type, reflecting the presence of free pigment rather than
RBCs. Four subjects underwent complete upper and lower urinary tract
investigation in the absence of detectable urine pigment. The results
were normal, except for mild hypokalemia in three of them, corre-
sponding most likely to urinary loss secondary to repeated cellular
lysis. Two patients were studied before and after a drumming session:
one patient presented obvious hemolysis after playing, with pinkish
plasma, LDH 777 UI, haptoglobin 0.2 g/liter and hemoglobinuria with
10.6 g/liter, and proteinuria containing, in particular, an abundant
amount of /32 microglobin (J32M). This abundant amount of /32M in urine
is likely linked to competitive tubular reabsorption of f32M and hemo-
globin. We conclude that hemolysis is a frequent phenomenon during
lengthy bare-handed drumming sessions caused, no doubt, by repeated
microtrauma to the fingertips and palms. This results in gross or
non-visible hemoglobinuria and proteinuria. Their discovery after
drumming sessions and later disappearance require no further urinary
tract exploration.
A new metabolic drug-induced nephrolithiasis: Oxalic stones in patients
treated with piridoxilate. M. Daudon, R.J. Reveillaud, V. Kessali, M.
Normand, and P. Jungers. Laboratoire Cristal, C.H. Saint-Cloud,
Centre d'hémodialyse, Clinique de Toutes-Aures, Manosque,
Polyclinique Saint-Martin, Pessac and Clinique Néphrologique,
C.H.U. Necker, Paris, France. Piridoxilate (P) is an equimolecular
combination of glyoxylic acid and pyridoxine, the latter being added to
prevent excessive production of oxalate from glyoxylate. The drug is
used in the treatment of coronary disease and/or arteritis; the usual
daily dose ranges from 110 to 165 mg of glyoxylate and 300 to 435 mg of
pyridoxine. We observed seven patients, five male and two female,
aged 43 to 80 years, who developed oxalic lithiasis after being treated
with P for 9 months to 8 years. Six of them had no past history of
urolithiasis. Stone formation clinically manifested 6 months to 5 years
after starting P treatment. Four patients had bilateral, multiple, (10 to
70) and rapidly recurrent stones, whereas three had a single stone, and
surgery was performed in six. Urine oxalate concentration, determined
in only three patients, was 0.43 to 0.50 mmole/liter while on treatment,
and decreased 0.13 to 0.23 mmole/liter after P withdrawal. The mor-
phology of the stones of six patients was similar; it was of the
whewellite type, but constantly with two peculiarities: (1) an irregular
mammillary structure with a highly indented surface; and (2) on cross
section, a powdered, unorganized nucleation area. Infrared spectros-
copy (IR) revealed the typical spectrum of whewellite, both on the
surface and the section, including the nucleation zone. Urinary sedi-
ment examination was performed in two patients while on treatment by
P and revealed unusual crystalluria. Some crystals had an asymmetrical
hexagonal shape; others were rectangular with convex extremities. I R
analysis revealed oxalate trihydrate, a type of crystal usually not found
in the urine. After P withdrawal, hexagonal and rectangular crystals
disappeared. The seven patients have been followed for 3 to 30 months
after P was stopped, and no recurrence of stones has been experienced
by any of them. In conclusion, piridoxilate-induced urolithiasis appears
to be more severe than most other drug-induced lithiasis reported to
date. The disease is usually active, with production of rapidly recurrent
stones, probably due to the high concentration of oxalic acid and
presence of calcium oxalate crystals in urine. In patients on long-term
treatment with F, a periodic search for urolithiasis is needed, and in
stone formers such treatment should be avoided.
Reversible acute renal failure (ARF) during enalapril treatment In a
patient without renal artery stenosls (RAS). F. Brivet, D. Roulot, A.
Poitrine, and J. Dormont. A. Beclere Hospital, Clamart, France. ARF
can occur during converting enzyme inhibition (CEI) for therapy for
hypertension (HBP) due to single-kidney or bilateral RAS. We report
ARF in a patient treated with CEI for HBP without RAS. The patient,
a 62-year-old man was readmitted for HBP (260/150 mm Hg) despite
clonidine, dihydralazine, amiloride, and hydrochlorothiazide treatment.
Two years before, he was admitted for malignant varicella with ARF,
encephalitis, hepatitis, pancreatitis, and HBP. Renal biopsy revealed
focal glomerular sclerosis. At discharge, HBP was controlled; renal
function was slightly impaired (creatinine 147 /.Lmoles/liter). On
readmission, despite increased therapy, HBP remained uncontrolled.
Therefore, enalapril (10 mg/day) was initiated. Twenty hr later, ARF
occurred (creatinine 400 jimoles/liter) without weight loss. ARF was
reversible after enalapril withdrawal. No RAS was revealed by DIVA.
To our knowledge, this is the first report of ARF during CEI treatment
without RAS.
Inefficiency of early prophylactic hemodialysis (HI)) in cis-platinum(CDDP) overdose. F. Brivet, f.M. Paviovitch, A. Gouyette, M.L.
Cerrina, G. Tchernia, and J. Dormont. Hôpital A. Bleclere, Clamart,
France. CDDP may induce nephrotoxicity. HD was performed 4 hr
after a CDDP overdose (200 mg/m2/8 hr), with the aim of limiting
nephrotoxicity and myelosuppression. A 41-year-old nurse received on
day 5 of the first course of polychemotherapy (stage III ovarian
carcinoma) a double dose of CDDP. Day 1: doxorubicin (25 mg/m2),
VM 26 (35 mg/m2); days 3 to 4: CPM (200 mg/rn2), SFU (350 mg/rn2). At
day 5, a 100 mg/rn2 CDDP perfusion was administered, inadvertently
followed 6 hr later by a second dose (100 mg/rn2). Nausea, diarrhea,
headache, and metallic taste occurred 1 hr after second dose. Thus,
25% mannitol and 5% dextrose perfusions were started. HD was
initiated in ICU 4 hr after the end of the second dose. Despite HD and
osmotic polyuria, acute renal failure (ARF), metabolic acidosis, and
febrile aplasia occurred 5 days after overdose. Patient (pt) was treated
with 3 HD and nonspecific supportive therapy. Two weeks after CDDP
perfusion, pt was discharged in good condition (creatinine 108
rnoles/liter). During the second course of chemotherapy (CDDP 50
mg/rn2), ARF did not recur. HD ineffectiveness in preventing ARF is
explained by lack of CDDP removal: 4.21 jg platinum/ml before HD
versus 4.08 g/ml after HD. CDDP plasma protein binding might be
total 4 hr after perfusion. HD is not recommended in CDDP overdose;
plasma exchange might be considered.
Theophylline metabolites in the serum of uremic patients and in
dialysis. Toxicity risks. G. Lachdtre, J.P. Charmes, P. Pignolet, M.
Rincé, C. Leroux-Robert, and G. Nicot. Service de Pharmacologic
Clinique, Service de Nephrologie, Hópital Universitaire Dupuytren,
Limoges, France. Total body theophylline clearance in uremic patients
is similar to that reported for patients with normal renal function. It is
the same in subjects undergoing hemodialysis on the nondialysis day.
Hemodialysis accelerates theophylline elimination. Nevertheless, we
observe clinical toxic signs in dialysis patients with theophylline treat-
ment and serum theophylline levels below 15 sg/ml. As several
theophylline metabolites have been described, we uscd an HPLC
method for determining serum concentrations of free and total
theophylline and of its metabolites (l-methylxanthine, 3-methylxan-
thine, 1-methyluric acid, and 1 ,3-dimethyluric acid) in ten patients with
normal renal function and in ten uremic patients, five in end-stage renal
failure and five on maintenance hemodialysis. Other xanthine deriva-
tives (1 ,7-dimethylxanthine, theobromine, and caffeine) were also eval-
uated in all these patients. Subjects with renal failure demonstrate
theophylline values within or somewhat below the therapeutic range,
with free fractions similar to those observed in healthy subjects.
Moreover, the serum levels of theophylline metabolites observed in
uremic patients are markedly increased. Since some of these metabo-
lites have pharmacological and biochemical activities similar to those of
their parent compound, we advise reconsidering the doses of theophyl-
line usually given to patients with deteriorated renal function.
An alternative means of blood access for chronic hemodialysis patients.
The subcutaneous fixed superficial humeral artery. J. Zingraff, C. Naret,
T. Drü eke, and M. Lacombe. Necker Hôpital, Paris, France. Standard
techniques of arteriovenous access to the circulation may be unsuitable
in some hemodialysis patients because of the occurrence of hemody-
nainic complications or the exhaustion of all peripheral veins. We
report on our experience in six hemodialysis patients in whom a
subcutaneous fixed superficial humeral artery was used for long-term
blood access. Mean age of the group was 55 years (range, 18 to 73). All
these patients, four female and two male, were treated by hemodialysis
during a mean period of 7 years (range, 1.5 to 18), and all had previous
arteriovenous access devices accounting for the dilation of the humeral
artery in the homolateral arm. The indication for the choice of a purely
arterial access procedure was cardiac failure, at least partially due to an
overfunctioning a-v fistula, in three patients, vascular steal syndrome in
one patient, and exhaustion of all suitable venous sites in the two
others. The period of observation ranged from 12 to 27 months (mean,
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17). Arterial punctures were performed three times weekly during a
mean period of 13.5 months (range, 0.5 to 26 months). No serious
complications occurred. However, aneurysmal dilatation developed in
two patients; in one, it was only of minor degree, but, in the other, the
aneurysm was much larger. Only one hematoma was noteworthy in one
patient. In conclusion, we propose the subcutaneous fixed superficial
artery as an alternative means of blood access in some hemodialysis
patients with precarious access problems and several failures of arteri-
ovenous devices.
A portable hemodialysis (HI)) system with sorbent regeneration (SR) of
dialysate (D). G. Mourad, R. Issautier, and C. Mion. Service de
Nephrologie, Hôpital Lapeyronie, Montpellier, France. To facilitate
patient travel, we developed a simplified portable HD system utilizing
the sorbent cartridge D3160 (O,T., Doxtel, Netherlands) for SR of D.
There are three main components: (1) a compact disposable plastic
container (DPC), 16 x 21 x 33 cm), used as D reservoir and surround-
ing the cartridge, assembled with a disposable PVC closed circuit for D
recirculation; (2) a dialyser with A+V blood (B) lines; and (3) a roller
pump receiving the pump segments of both B+D tubings, inducing
similtaneously B+D flows in their respective circuits (mean SD,
mi/mm): QB 372 30, QD 235 19). D, prepared as recommended for
SR, was kept at a constant temperature by external warming of DPC.
Standard monitoring was used for B+D circuits. Simultaneous priming
of D+B circuits permits quick and easy HD start. Our system was
assessed in 20 patients during 26 4-hr HD sessions. D composition,
checked every 30 mm, showed an increase in D[Na] from 120 13 (TO)
to 152 3 mmoles/liter (T240) with a stable pH (6.93 0.24 to 6.71
0.18). Extraction coefficients from B were: urea 0.58 0.7; creatinine
0.50 0.06; uric acid 0.67 0.06; P04 0.36 0.14. B[AlI was 25.5
12 before and 29 14 /.Lg/Iiter alter HD. D[A1] (mean SD, pg/liter)
remained below 10 (TO 7.42 6.13; T60 4.1 5.4; T120 4.1 5.4; T180
4.6 4; T240 8 5.5) during HD sessions. HD tolerance was excellent
despite an ultrafiltration rate of 2.55 1.16 liters/session. Our system is
an acceptable alternative to chronic HD system. Its compactness and
portability permits greater patient freedom.
Disappearance of mesanglal IgA deposits in acute poststreptococcal
glomerulonephritis superimposed on IgA nephropathy. P. Simon, M.P.
Ramée, J.P. Grünfeld, D. Droz, G. Grateau, G. Cam, and K.S. Ang,
C.H. Saint-Brieuc, C.H. U. Pontchaillou Rennes, Hôpital Necker,
Paris, France. Spontaneous disappearance of mesangial IgA deposits
has never been documented in IgA glomerulopathy (GN). It has been
rarely reported alter renal transplantation or plasma exchanges. We
report two cases in which disappearance of IgA deposits occurred
concomitantly with acute poststreptococcal glomerulonephritis (AGN)
superimposed on IgA ON. A 27-yr-old man with Berger's disease of 15
years' diagnosis and a 41-yr-old woman with IgA GN and alcoholic liver
cirrhosis developed acute renal failure (peak serum creatinine 540 and
487 zmo1es/liter, respectively with heavy proteinuria during streptococ-
cal infection (rhinopharyngitis and surinfection of ascites fluid, respec-
tively). In both patients (pts), serum antistreptolysins 0 were elevated
and in one of them serum complement (CH5O and C3) decreased
transiently. A second renal biopsy was performed in both pts. By light
microscopy, there was diffuse endocapillary and mesangial glomerular
proliferation with numerous neutrophls; humps were detected in one pt.
These lesions had not been found on initial biopsy specimens. By
immunofluorescence, IgA mesangial deposits had completely disap-
peared in one Pt and were clearly attenuated in the other, whereas
diffuse granular C3 deposits were observed along the GBM in both.
Within a few weeks, renal function and proteinuria returned to basal
levels: serum creatinine 210 and 150 moles/liters, proteinuria 5.2 and
2 g/24 hr, respectively. In conclusion, AGN may explain reversible
renal failure in pts with IgA ON. Disappearance of IgA deposits may
occur concomitantly, perhaps related to phagocytic activity of neutro-
phils that infiltrate glomeruli in AGN.
